XL147 (Synonyms: Pilaralisib, SAR245408) |
| カタログ番号GC12709 |
XL147 (XL147 アナログ) は、代表的かつ選択的な PI3Kα です。特許WO2012006552A1から抽出した阻害剤、表1の化合物147。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 956958-53-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
XL147 is a potent and orally active inhibitor that targets Class I PI3Ks with IC50 values in the nanomolar level. It has PI3K inhibition activities with IC50 of 39,383,36, and 23nM for PI3Kα, PI3Kβ, PI3Kδ,PI3Kγ, respectively.[1]
PI3Ks are a family of enzymes, which phosphorylate the 3'- OH position of the inositol ring of phosphoinositides.PI3Ks are divided into three classes based on structural features and in vitro lipid substrate specificity. The three class-Ia PI3K (p110 α / β / δ ) and the sole class-Ib PI3K (p110 γ ) couple growth factor receptors and G-protein-coupled receptors, respectively, to a wide range of downstream pathways. Signal transduction via the PI3K/Akt pathway is essential for regulating cellular functions, including proliferation, survival, migration, motility and tumorigenesis, in a variety of cell types. XL147 is a reversible ATP-competitive inhibitor, yet is highly selective against over 130 human protein kinases.[1]
MCF7 and PC-3 cell lines were treated with XL147 led to a reduction in the levels of phosphatidylinositol-3,4,5-tris-phosphate (PIP3) and decline in phosphorylation of AKT and ribosomal S6 protein, which are two downstream effectors of PI3K signaling. Furthermore, XL147 demonstrates potent anti-angiogenic effects in tubule formation driven by vascular endothelial growth factor and potent inhibition of cell migration stimulated by hepatocyte growth factor . [1]
Oral administration of XL147 results in eminent inhibition of tumor growth in mice bearing xenografts in which PI3K signaling is activated, including the PTEN-deficient PC-3 prostate adenocarcinoma and MDA-MB-468 breast adenocarcinoma models, and the K-Ras activated Calu-6 non-small cell lung carcinoma model. These effects on pathway signaling correlate with inhibiting tumor cell proliferation, inhibiting tumor angiogenesis, and inducing apoptosis as determined by immunohistochemical analysis. Moreover, combining XL147 in these models with other mTOR/Raptor inhibitors, such as the chemotherapeutic agents paclitaxel and carboplatin, results in enhanced anti-tumor efficacy associated with a substantial increase in apoptosis when compared to the individual agents alone. [2]
References:
1.Shapiro G, Edelman G, Calvo E, et al. Targeting aberrant PI3K pathway signaling with XL147, a potent, selective, and orally bioavailable PI3K inhibitor[J]. Proc 97th Annu Meet AACR, 2007: 14-18.
2.Traynor A M, Kurzrock R, Bailey H H, et al. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors[J]. J Clin Oncol, 2010, 28(15s): 3078.
| Cell experiment [1]: | |
|
Cell lines |
Rhabdomyosarcoma cell lines, neuroblastoma cell lines |
|
Preparation method |
Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
10 nM-100 μM, 6–12 h |
|
Applications |
In PPTP cell lines, XL147 (100 μM) demonstrated cytotoxic activity with the IC50 values ranged from 2.7 μM (CHLA-10) to 24.5 μM (TC-71).There was a trend for lower values for the rhabdomyosarcoma panel (median rIC50 5.6 μM) and higher values for the neuroblastoma panel (median rIC50 19.5 μM). XL147 showed higher sensitivity for the rhabdomyosarcoma cell lines and lower sensitivity for the neuroblastoma cell lines. |
| Animal experiment [1,2]: | |
|
Animal models |
Solid glioma xenografted mouse model |
|
Dosage form |
Oral administration, 100 mg/kg, daily for 14 days |
|
Application |
In BALB/c nu/nu mice, Pilaralisib (100 mg/kg, p.o.) induced tumor growth inhibition for solid glioma xenografts. Pilaralisib was well tolerated, with only 0.7% toxicity rate in the treated groups. In athymic female mouse, Pilaralisib (100 mg/kg, p.o.) significantly delayed tumor growth without significant drug-related toxicity. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Reynolds C P, Kang M H, Carol H, et al. Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program[J]. Pediatric blood & cancer, 2013, 60(5): 791-798. [2]. Chakrabarty A, Sánchez V, Kuba M G, et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors[J]. Proceedings of the National Academy of Sciences, 2012, 109(8): 2718-2723. | |
| Cas No. | 956958-53-5 | SDF | |
| 同義語 | Pilaralisib, SAR245408 | ||
| Chemical Name | N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide | ||
| Canonical SMILES | CC1=CC=C(C=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4 | ||
| Formula | C21H16N6O2S2 | M.Wt | 448.52 |
| 溶解度 | ≥ 22.45mg/mL in DMSO with gentle warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2296 mL | 11.1478 mL | 22.2955 mL |
| 5 mM | 0.4459 mL | 2.2296 mL | 4.4591 mL |
| 10 mM | 0.223 mL | 1.1148 mL | 2.2296 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *